Ndabizi ko bigoye gusobanura mu magambo icyo wumva iyo muganga wawe akubwira ko urwaye kanseri y'ibere. Ni ibisanzwe kugira ibibazo byinshi n'ubwoba bwinshi biza mu mutwe wawe. Ariko kimwe mu bintu by'ingenzi bishobora kugufasha muri uru rugendo rutoroshye ni ugusobanukirwa neza imiterere ya kanseri yawe. Kumenya icyiciro cya kanseri, ubwoko bwayo, ingano yayo, na zimwe muri poroteyine ziri mu turemangingo twa kanseri yawe ni ingenzi cyane mu gufata icyemezo cyo kuyivura.
Mu magambo make, HER2-Negative ni iki?
Reka tubisobanukirwe muri ubu buryo. Uturemangingo mu mubiri wacu tumeze nk'utuzu duto. Izi nzu zifite 'antenna' zidasanzwe zakira ubutumwa buturutse hanze. Mu buvuzi, izi 'receptors' tuzita. Ni muri izi antene aho ingirabuzimafatizo yakira ubutumwa nko 'gukura' no 'gucikamo ibice'.
HER2 (Human Epidermal Growth Factor Receptor 2) ni imwe muri izo antene zidasanzwe. HER2 ifasha kugenzura imikurire y'uturemangingo tuzima. Ariko, uturemangingo twa kanseri rimwe na rimwe dukora iyi antene ya HER2 cyane, cyane cyane kuruta uko bisanzwe. Hanyuma kanseri yakira ubutumwa buhoraho buyibwira 'gukura', maze kanseri igatangira gukwirakwira vuba cyane. Iyi ndwara tuyita HER2-Positive .
Rero, niba muganga wawe avuze ko kanseri y'ibere yawe ari HER2-negative , bivuze ko uturemangingo twa kanseri yawe tudafite iyi antene ya HER2 y'inyongera. Muri make, kanseri yawe nta kintu kinini ifite gituma ikura vuba.
Mu by’ukuri iyi ni inkuru nziza ku rugero runaka, kuko kanseri zitagira HER2 zikunze kuba mbi cyane ugereranyije na kanseri zitagira HER2. Inyinshi muri kanseri z’ibere ku isi zishyirwa mu cyiciro cya HER2-negative.
Ni gute wamenya neza uko kanseri yawe ihagaze kuri HER2?
Ibimenyetso bya kanseri ya HER2-negative na HER2-positive birasa. Muganga wawe ntashobora kukubwira ubwoko bw'indwara yawe agusuzumye gusa. Azakenera gufata icyitegererezo gito cya kanseri yawe (biopsy) maze akayipima. Iki kizamini kizagaragaza neza ingano ya poroteyine ya HER2 iri mu turemangingo twa kanseri.
Tugomba kureba ibirenze HER2 gusa!
HER2 si yo yonyine igira ingaruka ku mikurire ya kanseri. Hari ubundi bwoko bubiri bwa receptors (receptors za hormone - HR) mu mubiri wacu zishobora kumva imisemburo.
- Udukoresho twa Estrogen (ER)
- Udukoresho twa Progesterone (PR)
Iyo izi receptor ziri ku tunyangingo twa kanseri, imisemburo ya estrogen na progesterone bishobora gufasha kanseri gukura. Abaganga baganira kuri izi receptor zose hamwe. Ibi bivuze ko kanseri yawe ya HER2-negative ishobora kugabanywamo ubwoko bubiri:
1. HR-Positive / HER2-Negative: Ibi bivuze ko kanseri idaterwa na HER2, ahubwo iterwa n'imisemburo. Iyi ni yo kanseri y'ibere ikunze kugaragara cyane .
2. HR-Negative / HER2-Negative: Ibi bivuze ko kanseri idakunze kugaragara kuri HER2 cyangwa imisemburo. Kubera ko izi receptor eshatu zose (HER2, ER, PR) zitaboneka, ubwo bwoko bwitwa Triple Negative .
Kumenya ibi bintu byose bizagufasha wowe na muganga wawe gusobanukirwa neza imiterere y’umubiri wa kanseri yawe, bizagufasha guhitamo uburyo bwiza kandi bwiza bwo kuvura .
Ni ubuhe buryo bwo kuvura kanseri ya HER2-negative?
Kubera ko kanseri yawe ari HER2-negative, ntuzahabwa uburyo bwo kuyivura, bugamije poroteyine ya HER2. Ibyo biterwa nuko imiti igomba kugira antene ya HER2 ku turemangingo twa kanseri kugira ngo ikore. Ahubwo, ubundi buryo bwo kuyivura buzatoranywa hashingiwe ku ntera ya kanseri yawe ndetse niba iterwa n’imisemburo.
- Kubagwa no gukoresha imirasire: Iyo kanseri igaragaye hakiri kare, kubagwa bishobora kuyikuraho burundu. Ubuvuzi bushingiye ku mirasire bushobora kandi gutangwa mbere cyangwa nyuma yo kubagwa.
- Ubuvuzi bwa Endocrine/ Hormonal : Ubu buvuzi ni ingenzi cyane niba kanseri yawe ifite HR-Positive/HER2-Negative. Bukora mu kugabanya urugero rw'imisemburo nka estrogen mu mubiri. Iyo imisemburo ivuyeho, uturemangingo twa kanseri dutakaza ubutumwa bwo gukura, kandi kanseri ishobora kugabanuka cyangwa igahagarara gukura.
- Chimiotherapie: Chimiotherapie rimwe na rimwe ishobora gutangwa hamwe n'imiti igabanya ubukana bwa kanseri ya HR-positive / HER2-negative. Ibi biterwa n'ibintu nk'urwego n'icyiciro cya kanseri, imyaka yawe, n'ubuzima bwawe muri rusange. Hari igihe ingaruka mbi za chimiotherapie zishobora kuruta inyungu, bityo rero ni ngombwa kuvugana na muganga wawe ku cyakubera cyiza.
- Ubuvuzi bw'ubudahangarwa bw'umubiri: Niba kanseri yawe ifite ubukana butatu kandi iteye imbere, kandi ifite indi poroteyine yitwa PD-L1, ubu buvuzi bushobora kuba amahitamo. Bukora mu gukangura ubudahangarwa bw'umubiri wawe kugira ngo burwanye kanseri.
Icyerekezo n'Isuzuma ry'Ibizakorwa
Ikintu cy'ingenzi kuri kanseri y'ibere ni ukuyisanga mbere yuko ikwirakwira mu bindi bice by'umubiri. Niba kanseri yawe ya HER2-negative iherereye mu ibere, igipimo cyo kubaho mu myaka 5 kiba kiri hejuru cyane. Ibi ni ukuri cyane cyane iyo kanseri yawe ifite HR-positive.
Kanseri eshatu zidafite ingaruka nziza ziragoye kuvura kuko zititabira imiti igabanya ubukana bw'imisemburo cyangwa imiti ikoreshwa na HER2. Zishobora kandi kuba zikomeye kurushaho.
Dore igipimo cy'ubuzima bw'imyaka 5 ugereranyije n'icyiciro cya kanseri. Ibi ni impuzandengo gusa, ibuka ko imimerere yawe bwite ishobora kuba itandukanye.
| Ubwoko bwa kanseri | Uko byakwirakwiriye | kubaho imyaka 5 ugereranije |
|---|---|---|
| HR-Positive / HER2-Negative (Ubwoko bukunze kugaragara cyane) | Bigarukira ku ibere gusa (Byashyizwe mu gace runaka) | 100% |
| Ikwirakwira mu tunyangingo tw’amaraso turi hafi aho (mu gace) | 90% | |
| Kure | 31% | |
| Inyangingo eshatu (Indwara ya HR-Negative / HER2-Negative) | Bigarukira ku ibere gusa (Byashyizwe mu gace runaka) | 91% |
| Ikwirakwira mu tunyangingo tw’amaraso turi hafi aho (mu gace) | 65% | |
| Kure | 12% |
Ntugahangayikishwe n'iyi mibare. Iyi ni impuzandengo y'abantu ibihumbi. Uko umuntu abibona bizaterwa n'ibintu byinshi, harimo n'uko umubiri we witabira kuvurwa ndetse n'ubuzima bwawe muri rusange. Rero, bwira muganga wawe ku bijyanye n'uburwayi bwawe ndetse n'ibindi bizamini ushobora gukenera.
Ubutumwa bwo kujyana mu rugo
- HER2-Negative bivuze ko uturemangingo twa kanseri yawe tutagira poroteyine y'ingenzi ituma dukura vuba. Ibi akenshi bituma izi kanseri zidatera ubukana.
- Nubwo kanseri yawe yaba ari HER2-negative, kumenya niba ishobora kwanduzwa n'imisemburo (HR-positive) cyangwa atari yo (HR-negative) ni ingenzi mu kugena uburyo bwo kuyivura.
- Uburyo bwo kuvura buterwa n'ubwoko n'urwego kanseri yateye, ndetse n'ubuzima bwawe bwite. Kubagwa, kuvurwa hakoreshejwe imirasire, kuvurwa hakoreshejwe imisemburo, na chimiotherapie ni bwo buryo bw'ingenzi bwo kuvura.
- Uru rugamba rwo kurwanya kanseri si ikintu ugomba gukora wenyine. Vugana na muganga wawe ku bibazo byawe byose n'ubwoba bwawe. Kugira amakuru nyayo ni byo bigutera imbaraga nyinshi muri uru rugendo.
💬 Comments (0)
Kwipimisha kanseri y'ibere, kwisuzuma no kwirinda byakozwe byoroshye. Kanseri y'ibihaha
Ishyirireho intego ya calorie hanyuma ubare itariki yo kugabanya ibiro.